Study on the effect of tadalafil on bladder blood flow in patients with lower urinary tract symptoms due to benign prostatic hyperplasia

Study on the effect of tadalafil on bladder blood flow in patients with lower urinary tract symptoms due to benign prostatic hyperplasia - Effect of tadalafil on bladder blood flow in benign prostatic hyperplasia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020658

Enrollment

Registered

2016-02-01

Start date

2016-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with lower urinary tract symptoms due to benign prostatic hyperplasia

Interventions

Administration of tadalafil 5mg once per day for 8 weeks

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: I-PSS 13 or more, prostate volume 20ml or more, Qmax on uroflowmetry between 4 ml/sec and 15 ml/sec

Exclusion criteria

Exclusion criteria: postvoid residual urine 150 ml or more, uncontrolled diabetes mellitus, patients taking medication for lower urinary tract symptoms, patients who underwent surgery or radiation to the prostate

Design outcomes

Primary

Measure	Time frame
Change in resistive index of vesical artery on doppler ultrasound at 8 weeks after tadalafil administration	—

Countries

Japan

Contacts

Public ContactHidehiro Kakizaki

Asahikawa Medical University Department of Renal and Urologic Surgery

kaki@asahikawa-med.ac.jp0166-68-2533

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026